{"name":"Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)","slug":"durata-therapeutics-international-bv-an-affiliate-of-actavis-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOaTZWY1JnbWlKbERMcXhnQkJwSkVBWTZ3dmRrS3ZnVjhrR052LVM5djF4Q3dEZFJ1RTctTzBGRmE3T3o1U0hwWHVFcURjbThYRjI0NGtzWktvNXlDQUZxOTNVQ2Z2V0l0LUstUU9zWjJFZTQ0anp3Sm92RmJ3MHVJMXEzdGRHRXRLV3M3UTdWaC1HNWw1MW9tS00xTHl0Qnd0TFZmcmdqRnlCb2NWcEV4dHpmbHAwMGF2ZUQtVVBQQTF6bjF2VHFTZlpfbU9zV2c?oc=5","date":"2015-03-02","type":"regulatory","source":"PR Newswire","summary":"Actavis Receives Approval from the European Commission for XYDALBA™ (dalbavancin) - PR Newswire","headline":"Actavis Receives Approval from the European Commission for XYDALBA™ (dalbavancin)","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}